Takeover sparks jobs fear at Welwyn Garden City firm
THE threat of job losses among 800 WGC workers has surfaced after the takeover of a pharmaceutical giant. Schering-Plough, which has its UK base in Shire Park, has been bought out by rivals Merck in a multi-billion pound deal. The move will create a new g
THE threat of job losses among 800 WGC workers has surfaced after the takeover of a pharmaceutical giant.
Schering-Plough, which has its UK base in Shire Park, has been bought out by rivals Merck in a multi-billion pound deal.
The move will create a new global drugs giant and see the two US firms - with a combined UK workforce of nearly 3,000 - join forces later this year.
There are fears it could trigger a 15 per cent reduction in the combined global workforce.
You may also want to watch:
Schering-Plough employs 51,000 around the world including 1,500 in the UK - more than half of which work in or from Shire Park.
But a spokesman this week told the WHT it was too early to say what impact the takeover would have on staff numbers here.
Most Read
- 1 Dangerous Welwyn Garden City domestic abuser who slashed ex-girlfriend's throat jailed
- 2 Safety check and risk assessment failings for hundreds of Welwyn Hatfield council houses
- 3 When is Team GB cycling star Laura Kenny in action at Tokyo 2020 Olympics?
- 4 The latest court results for Welwyn Hatfield and Potters Bar
- 5 Community reacts to closure of overnight Urgent Care Centre service at New QEII Hospital
- 6 Water safety advice issued following lake drowning
- 7 New report reveals 28 Covid deaths at Hatfield care home
- 8 9 things you didn’t know about the making of Band of Brothers
- 9 Henry Moore Foundation in Hertfordshire appears in new Fake or Fortune? series on BBC One
- 10 The changing nature of Potters Bar high street
The �29bn deal, to be paid in shares and cash, will bring together the makers of blockbuster treatments including cholesterol drugs Zetia and Vytorin.
Schering-Plough chairman Fred Hassan said: "By harnessing the strengths of both companies, the combined entity will be well-positioned to further deliver on our shared goal of discovering new therapies for patients to help them live healthier, happier lives.
